Analysts expect Abivax S.A. to report revenue of 4.57 M for 2026, against a range of 4.15 M to 4.99 M. The most recent reported year, 2025, came in at 5.33 M, a 29.0% miss against the 7.51 M consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 2.29 M | 106,230.00 | 4.95 M | 14.10 M | 5.33 M | - | - | ||
| High Estimate | 761,160.35 | 1.83 M | 467,852.97 | 9.94 M | 8.07 M | 4.99 M | 120.51 M | ||
| Low Estimate | 633,649.61 | 1.55 M | 432,097.93 | 9.03 M | 6.95 M | 4.15 M | 105.63 M | ||
| Consensus Estimate | 697,404.98 | 1.69 M | 449,975.45 | 9.48 M | 7.51 M | 4.57 M | 113.07 M |
Analysts expect Abivax S.A. to report earnings per share of -4.02 for 2026, against a range of -4.22 to -3.82. The most recent reported year, 2025, came in at -5.53, a 26.5% miss against the -4.37 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -2.89 | -3.52 | -3.68 | -3.13 | -5.53 | - | - | ||
| High Estimate | -3.24 | -2.71 | -1.89 | -2.73 | -4.09 | -3.82 | -3.08 | ||
| Low Estimate | -3.60 | -3.11 | -2.21 | -2.91 | -4.65 | -4.22 | -3.74 | ||
| Consensus Estimate | -3.42 | -2.91 | -2.05 | -2.82 | -4.37 | -4.02 | -3.41 |